Neonates exposed prenatally to opioids will often develop a collection of withdrawal signs
known as neonatal abstinence syndrome (NAS). The incidence of NAS has substantially …

Background Neonatal abstinence syndrome (NAS) occurs following prenatal opioid
exposure. It is characterized by signs and symptoms indicating central nervous system …

Background: The evaluation and management of infants with neonatal abstinence syndrome
(NAS), the constellation of opioid withdrawal specific to newborns, have received renewed …

Background Neonatal abstinence syndrome (NAS) includes an array of symptoms impacting
opioid-exposed newborns (OEN) owing to postnatal withdrawal from in utero substance …

The incidence of neonatal abstinence syndrome (NAS) has increased dramatically during
the past 15 years, likely due to an increase in antepartum maternal opiate use. Optimal care …

Neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure is an
increasing problem. Variability in assessment and treatment of NAS has been attributed to …

Aims: To determine the monitoring and treatment of neonatal abstinence syndrome (NAS) in
neonatal intensive care units (NICUs) following opiate or polydrug exposure in utero …

Neonatal abstinence syndrome (NAS) is a result of the sudden discontinuation of fetal
exposure to substances that were used or abused by the mother during pregnancy …

Although a statement on Neonatal Drug Withdrawal was published in 1998 by the American
Academy of Pediatrics, pharmacologic management of neonatal abstinence syndrome …

Neonatal Abstinence Syndrome | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …